[ET Net News Agency, 14 September 2021] Genscript Biotech Corporation (01548) said
Legend Biotech Corporation (Legend Biotech), a non-wholly owned subsidiary of the company,
announced the start of a Phase 1 clinical trial in the United States for LB1901, an
investigational autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) therapy
for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL)
or cutaneous T-cell lymphoma (CTCL).
LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL
subtypes. The trial follows the U.S. Food and Drug Administration (the FDA) clearance of
the Investigational New Drug (the IND) application submitted by Legend Biotech. (RC)